Biohaven's key pipeline drug verdiperstat has failed to have any therapeutic effect in patients with the rare neurological disorder multiple system atrophy (MSA) – its lead indication – but
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.